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weeks or months following treatment.5 This chronic DOX
cardiotoxicity often presents as dilated cardiomyopathy
and is characterized by hypotension, cardiac dilation, and
decreased left ventricular ejection fraction. 
Efforts have been made to explore alternative therapies to
reduce DOX-induced cardiac dysfunction, such as the use of
slow infusions,6-8 antioxidants (probucol,9,10 ubiquinone,11
ambroxiron,12 α-lipoic acid,13 P-coumaric acid,14 and mela-
tonin15), iron chelators,16,17 and drug-encapsulated lipo-
somes.18 However, these strategies provide limited
improvements in cardiac function and in some instances
may have additional negative side effects for cancer patients. 
The benefits of chronic aerobic exercise training on the
cardiovascular system are well established. Regular aerobic
exercise has been shown to reduce the risk of heart disease,
control hypertension, and protect the heart against injury
caused by oxidative stress and apoptosis. In addition, as little
as 1 or 2 exercise bouts have been shown to preserve cardiac
function and protect the heart against oxidative stress.19,20
Although a growing body of evidence indicates that regular
aerobic exercise before DOX treatment can alleviate its neg-
ative cardiac side effects,3,21-24 it has yet to be determined
whether acute exercise can protect the heart against the car-
diac dysfunction that accompanies DOX treatment. 
Doxorubicin (DOX) is a highly effective anthracy-cline antibiotic used in the treatment of breast,bladder, lung, and thyroid carcinomas as well as
Hodgkin’s disease and non-Hodgkin’s lymphomas.
Unfortunately, the occurrence of a dose-related cardiomy-
opathy limits the clinical use of DOX. DOX treatment is
associated with acute cardiotoxicity that develops within
minutes of intravenous administration and is marked by
vasodilatation, hypotension, tachycardia, and cardiac
arrhythmias. Although these symptoms are reversible, this
early-onset cardiotoxicity has been shown to be predictive
of future heart failure.1,2 DOX treatment also significantly
compromises both systolic and diastolic cardiac function
in several animal models, which may be manifested
within days3,4 of DOX exposure and can be maintained for
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Numerous methods have been used to minimize the
cardiotoxic effects of the chemotherapeutic agent doxorubicin
(DOX), and most have had limited success. Chronic endurance
exercise has been shown to protect against DOX cardiotoxicity,
but little is known regarding the effects of acute exercise on
DOX-induced cardiac dysfunction. Purpose. The purpose of
this study was to determine the effects of a single bout of acute
endurance exercise on the cardiac dysfunction associated with
DOX treatment. Methods. Male Sprague-Dawley rats either
performed an acute exercise bout on a motorized treadmill for
60 minutes at a maximal speed of 25 m/min with a 5% grade
(EX) or remained sedentary (SED) 24 hours before receiving
either a 15-mg/kg DOX bolus dose or saline (SAL). Cardiac
function was then analyzed 5 days post injection using a
Langendorff isolated perfused heart model. In addition,
myocardial lipid peroxidation was analyzed as an indicator of
oxidative stress. Results. Doxorubicin treatment alone
(SED+DOX) promoted a significant decline in end-systolic
pressure (–35%), left ventricular developed pressure (–59%),
and the maximal rate of left ventricular pressure development
(–43%) as well as a 45% increase in lipid peroxidation products
when compared with SED+SAL (P < .05). Acute exercise 24
hours before DOX treatment, however, had a cardioprotective
effect, as end-systolic pressure, left ventricular developed pres-
sure, and the maximal rate of left ventricular pressure develop-
ment were significantly higher in EX+DOX compared with
SED+DOX (P < .05) and EX+DOX had similar levels of lipid
peroxidation products as SED+SAL Conclusions. An acute
exercise bout performed 24 hours before DOX treatment pro-
tected against cardiac dysfunction, and this exercise-induced
cardioprotection may partly be explained by a reduction in the
generation of reactive oxygen species.
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To our knowledge, only 2 studies have been conducted
that specifically address the effects of acute exercise on
DOX-induced cardiotoxicity. Ji and Mitchelll25 reported that
DOX administration after a single bout of acute exhaustive
exercise reduced the exercise-induced increase in cardiac
mitochondrial respiration. In an early report, Combs et al26
hypothesized that an acute bout of exhaustive exercise after
DOX treatment (18-23 mg/kg) would exacerbate the drug-
induced cardiotoxicity by decreasing survival rate. Results
indicated that the survival rate was actually increased in
those animals that had been subjected to exhaustive exercise
after DOX treatment. However, neither study attempted to
assess cardiac function in the context of acute exercise.
Therefore, the purpose of this study was to determine
whether a single acute bout of exercise performed before




Male Sprague-Dawley rats were obtained from Harlan
Sprague Dawley, Inc (Indianapolis, Ind). All animals were
housed 2 per cage in a temperature-controlled facility,
were provided standard rat chow and water ad libitum, and
were adapted to a 12/12-hour light/dark cycle. All proto-
cols were approved by the University of Northern Colorado
Institutional Animal Care and Use Committee and were in
compliance with Animal Welfare Act guidelines.
Acute Exercise Protocol
Animals were randomly assigned to 4 experimental groups:
exercise + DOX (EX+DOX), sedentary + DOX (SED+
DOX), EX + saline (EX+SAL), and SED+SAL. Animals in
the exercise groups were habituated to treadmill exercise
over a 2-week period. In the first week of acclimation, rats
ran 10 min/d, 3 d/wk at a speed of 10 m/min and 0% grade.
During the second week, animals ran 10 min/d, 3 d/wk at
a speed of 20 m/min and 0% grade. This acclimation pro-
tocol has been shown to have minimal effect on mitochon-
drial enzymes. Twenty-four hours after the acclimation
protocol, animals completed a single acute bout of exer-
cise. The 60-minute acute exercise bout was divided into
3 phases. During phase 1 (minutes 0-5) animals ran at 15
m/min and a 0% grade. During phase 2 (minutes 5-10)
animals ran at 23 m/min and a 0% grade. During phase 3
(minutes 10-60) animals ran at 25 m/min and a 5% grade.
Animals in both sedentary groups were placed on a non-
moving treadmill belt for 60 minutes.
Administration of DOX
Twenty-four hours following the completion of the acute
exercise bout or sedentary period, animals in the EX+DOX
and SED+DOX groups were treated with a 15-mg/kg
intraperitoneal bolus of DOX (Bedford Labs, Bedford,
Ohio). Animals in the EX+SAL and SED+SAL groups
received a single 0.5-mL intraperitoneal injection of 0.9%
sterile saline. 
Isolated Heart Preparation
Five days following SAL or DOX treatment, cardiac func-
tion was determined in isolated hearts using a constant-
pressure Langendorff perfusion preparation. All rats were
anesthetized with 50 mg/kg sodium pentobarbital (Sigma
Chemical, St. Louis, Mo) administered intraperitoneally
along with 500 U of sodium heparin serving as an antico-
agulant. The heart was rapidly excised, and the ascending
aorta was cannulated for retrograde perfusion with a Krebs
bicarbonate buffer consisting of 120 mM NaCl, 5.9 mM
KCl, 2.5 mM CaCl2, 1.2 mM MgCl, 25 mM NaHCO3, 17
mM glucose, and 0.5 mM EDTA. Buffer was saturated
with 95% O2/5% CO2 and maintained at 37°C in a water-
jacked reservoir suspended above the isolated heart, provid-
ing constant pressure of 80 mm Hg. To assess left
ventricular function, a microtip catheter pressure trans-
ducer (SPR-671; 1.4F catheter; Millar Instruments Inc,
Houston, Tex) was inserted into the left ventricular (LV)
cavity via the mitral valve for determination of LV pres-
sures. Following a 15-minute equilibration period, hearts
were paced at 300 beats/min via the atria using a stimulus
isolator in conjunction with a PowerLab/8e system
(ADInstruments, Colorado Springs, Colo). After an addi-
tional 5-minute stabilization period, baseline values of LV
developed pressure (LVDP), its maximal and minimal first
derivatives (dP/dtmax and dP/dtmin, respectively), end-systolic
pressure (ESP), and end-diastolic pressure (EDP) were
recorded using the PowerLab data acquisition system and
software. Immediately following the isolated perfused heart
protocol, the heart was removed and the left ventricle iso-
lated. Left ventricular tissue was frozen in liquid nitrogen
and stored for subsequent biochemical analyses.
Tissue Preparation
Approximately 100 mg of frozen left ventricular tissue was
pulverized with a porcelain mortar and pestle and trans-
ferred into ice-cold 20 mM Tris-HCl (ACS Reagent grade;
Sigma-Aldrich, St. Louis, Mo), pH 7.4, at a dilution of 1:5
wt/vol. Samples were then homogenized and sonicated.
Homogenates were centrifuged at 3000g for 10 minutes at
4°C, and the supernatant was obtained for biochemical
analysis. Total protein concentration was determined
using the method of Bradford with bovine serum albumin
(Pierce, Rockford, Ill) as the reference standard.
Myocardial Lipid Peroxidation
To examine the effect of DOX and acute exercise on
myocardial lipid peroxidation, malondialdehyde and
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4-hydroxy-alkenals (MDA+4-HAE) were analyzed in left
ventricular tissue using a commercially available assay kit
(OXIS International, Inc, Portland, Ore). The MDA+4-
HAE assay is based on the reaction of a chromogenic
reagent, N-methyl-2-phenylindole, with MDA+4-HAE at
45°C. To perform the assay, 200 µL of sample was added
to 10 µL of probucol and 640 µL of N-methyl-2-phenylin-
dole in acetonitrile and briefly vortexed. Next, 150 µL of
concentrated HCl was added, vortexed, and incubated at
45°C for 60 minutes. Samples were then centrifuged for
10 minutes at 10 000g to remove any interference from
turbidity. The supernatant was then transferred to a
cuvette and the absorbance was measured using a Genesys
20 spectrophotometer (ThermoSpectronic, Rochester,
NY) at 586 nm. Total MDA+4-HAE was estimated using
linear regression based on values obtained with an MDA
standard curve to yield the final concentration of MDA+4-
HAE (µM). All samples were assayed in duplicate, and any
samples varying more than 5% were reassayed. 
Statistical Analysis
Data from the 4 treatment groups were evaluated for dif-
ferences between groups by 2-way analysis of variance. In
the presence of significant F values, Tukey’s post hoc test




At the time of injection, there were no significant differ-
ences in mean body mass of rats among the experimental
groups (Table 1). Five days following treatment, animals
exposed to DOX lost an average of approximately 15% of
their body mass irrespective of their exercise status. In
addition, whereas heart mass/body mass ratio was signifi-
cantly higher in all groups in comparison to SED+SAL (P
< .05), only the SED+DOX group possessed a mean
absolute heart mass significantly lower than that of the
SED+SAL group (P < .05).
Cardiac Function
Figures 1 and 2 summarize cardiac function assessment.
There were no significant differences in any cardiac func-
tion variable between saline-treated groups, with the excep-
tion of dP/dtmin (–1732 ± 62 vs –2136 ± 86; P < .05). DOX
treatment resulted in a considerable degree of cardiac dys-
function as evidenced by a 162% increase in EDP, a 35%
decline in ESP, a 59% decline in LVDP, and a 43% decline
in dP/dtmax (P < .05 for all variables). Acute exercise before
DOX treatment (EX+DOX) completely preserved ESP, and
although LVDP and dP/dtmax were significantly lower than
SED+SAL, mean values for these variables were signifi-
cantly higher in comparison to SED+DOX (P < .05).
Despite the fact that acute exercise did not influence the
effects of DOX on EDP, dP/dtmin was significantly higher in
EX+DOX compared with SED+DOX (P < 0.5).
Myocardial Lipid Peroxidation
To provide an index of oxidative stress, MDA+4-HAE was
quantified in left ventricular samples (Figure 3). Sedentary
animals exposed to DOX showed a 45% increase in lipid
peroxidation 5 days after treatment. A single bout of acute
exercise 24 hours before DOX treatment completely elimi-
nated the DOX-induced increase in MDA+4-HAE at this
time interval, suggesting that the exercise significantly
reduced left ventricular lipid peroxidation.
Discussion
This study tested the hypothesis that an acute bout of
exercise before treatment with DOX would protect the
heart from DOX-mediated oxidative stress and the subse-
quent manifestation of cardiac dysfunction. This hypoth-
esis was based on observations that (1) DOX treatment
is associated with severe myocardial oxidative stress and
(2) acute exercise preserves cardiac function in models of
cardiac oxidative stress. Our results indicate that DOX
treatment caused severe cardiac dysfunction 5 days after
its administration, and this dysfunction was significantly
attenuated by prior acute exercise. ESP was completely
preserved in those animals subjected to an acute exercise
bout 24 hours before DOX exposure, whereas both LVDP
and dP/dtmax were significantly higher in exercised ani-
mals compared with their sedentary counterparts. In
addition, although the rate of pressure decline (dP/dtmin)
was significantly improved in EX+DOX animals, acute
exercise afforded no benefit for EDP. 
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Table 1. Animal Characteristicsa
SED+SAL EX+SAL SED+DOX EX+DOX
Injection 302 ± 3 306 ± 8 307 ± 7 324 ± 8
mass, g
Sacrifice 314 ± 3 320 ± 9 259 ± 10* 278 ± 9*
mass, g
∆body 12 ± 2 14 ± 2 –47 ± 12* –45 ± 6*
mass, g
Heart 1128 ± 24 1160 ± 35 965 ± 43* 1070 ± 56
mass, mg
HM/BM, 3.5 ± 0.07 3.9 ± 0.03* 3.7 ± 0.04* 3.8 ± 0.06*
mg/g
NOTES: SED =  sedentary; SAL = saline; EX = exercise; DOX = doxorubicin;
HM/BM = heart mass/body mass ratio.
aValues are mean ± SE.
*Significantly less than SED+SAL and EX+SAL (P < .05).
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Animals in the SED+DOX group demonstrated all of
the classic signs of DOX cardiotoxicity in this model.
Specifically, these animals had significant reductions in
body mass, heart mass, ESP, LVDP, and dP/dtmax as well as
increases in dP/dtmin and EDP. The cardioprotective effects
of acute exercise against DOX-induced cardiac dysfunction
5 days after treatment were remarkably similar to the pro-
tective effects afforded by chronic endurance exercise.
Our laboratory has shown that 8 weeks of voluntary wheel
running attenuated the in vitro cardiac dysfunction asso-
ciated with DOX perfusion in the isolated heart,23
and 12 weeks of treadmill running protected against DOX
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Figure 1. Left ventricular pressures in sedentary (SED) and acutely exercised (EX) animals 5 days following doxorubicin (DOX) treatment. EDP,
left ventricular end-diastolic pressure; ESP, left ventricular end-systolic pressure; LVDP, left ventricular developed pressure; LVDP × heart mass, ratio
of left ventricular developed pressure to heart mass in mm Hg per gram of heart mass; SAL, saline. Values are mean ± SE. *P < .05 vs SED+SAL;
†P < .05 vs SED+DOX.
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cardiotoxicity when DOX was administered in vivo.22 In
both studies, the most dramatic improvements were
observed with indicators of systolic function (ie, ESP, LVDP,
dP/dtmax), whereas little or no protection was provided
against increases in EDP. The same pattern of protection
appears to be provided by acute exercise in this model.
Although we report that acute endurance exercise pro-
tected against DOX-induced cardiac dysfunction via a
reduction in cardiac oxidative stress, it is possible that the
2 oxidative stressors (ie, DOX and exercise) exacerbated
cardiac oxidative stress in the days following treatment.
Our laboratory and others27-29 have reported that acute
endurance exercise increases cardiac oxidative stress.
Previously, we found that strenuous acute endurance exer-
cise resulted in a decrease in cardiac function and an
increase in oxidative stress that persisted for up to 48 hours
after the bout of exercise.30 In that study, indicators of
oxidative stress returned to baseline levels by 72 hours post
exercise. In the present study, MDA was not measured
until 5 days after DOX treatment and 6 days after the acute
exercise bout. Therefore, although there may have been
increases in oxidative stress during the 72 hours post DOX
treatment, exercise preconditioning clearly attenuated
the cardiac oxidative burden. This is supported by the
fact that 5 days after DOX treatment, sedentary animals
exhibited significant increases in MDA whereas exercised
animals showed levels of MDA that were not different from
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Figure 2. Maximal first derivatives (dP/dtmax, top) and minimal first
derivatives (dP/dtmin, bottom) of left ventricular pressure in sedentary
(SED) and acutely exercised (EX) animals 5 days following doxorubicin
(DOX) treatment. Values are mean ± SE. SAL, saline. *P < .05 vs
SED+SAL; †P < .05 vs SED+DOX.
Figure 3. Lipid peroxidation products in left ventricular homogenates.
Data are mean ± SE. *P < .05 vs SED × SAL. MDA, malondialdehyde;
4-HAE, 4-hydroxy-alkenal; EX, exercise; SED, sedentary; SAL, saline;
DOX, doxorubicin.
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sedentary controls. In addition, variations in cardiac oxida-
tive stress among these studies may be explained by varia-
tions in exercise modality (swimming vs running), exercise
duration (60 minutes vs exhaustive), or running protocol
(continuous vs progressive). 
The deleterious effects of DOX can be attenuated by
antioxidative agents, which supports the premise that
DOX-induced cardiotoxicity may be related to the produc-
tion of free radicals.9,31 Transgenic mice overexpressing car-
diac-specific metallothionein, a potent antioxidant, are
highly resistant to DOX cardiotoxicity as evidenced by an
attenuation of cardiac morphological alterations and the
prevention of sarcoplasmic and mitochondrial structural
changes observed in wild-type mice treated with DOX.32
Likewise, mice overexpressing the antioxidant enzyme cata-
lase show a significant reduction in DOX-related cardiac
dysfunction as measured by ventricular contractile force.33
Adaptations in the content and/or activity of enzymatic
and nonenzymatic antioxidant defenses following exercise
have been highly variable and inconsistent. Some studies
have reported no change34,35 or decreases36,37 in myocardial
antioxidants following endurance exercise training.
However, long-term exercise training has been shown to
increase the antioxidant status of the heart by increasing
cardiac glutathione levels and up-regulating cardiac cop-
per/zinc–superoxide dismutase, manganese superoxide dis-
mutase, catalase, and glutathione peroxidase activities and
protein expression.38-43 Additionally, a number of studies
have been conducted that describe the cardioprotective
effects of short-term exercise against ischemia–reperfusion
injury, a model that is associated with myocardial oxidative
stress. These studies indicate that 5 bouts,44,45 3
bouts,43,44,46 2 bouts,20 or even 1 bout19,47,48 of exercise can
improve postischemic cardiac function. Improved function
in this model has been associated with an enhancement in
antioxidant defenses,44,48 an increased expression of heat
shock protein,46,48 and an up-regulation in the inducible
form of nitric oxide synthase.47 Although such myocardial
adaptations may contribute, collectively or independently,
to exercise-induced cardioprotection, several studies have
shown that increases in antioxidants, heat shock protein, or
nitric oxide synthase are not necessarily a requisite for car-
dioprotection afforded by acute exercise.19,20,49 Nevertheless,
a single bout of acute exercise did attenuate increases in
myocardial MDA, and this was associated with a preserva-
tion of cardiac function. Thus, an increase in antioxidant
defenses is a viable mean by which acute exercise could
protect against DOX cardiotoxicity. 
Conclusion
These are the first data indicating that as little as 1 bout of
exercise can alleviate the cardiac dysfunction associated
with DOX exposure. The protective effects of exercise were
manifested as a preservation of peak systolic pressure,
developed pressure, the peak rate of pressure development,
and the peak rate of pressure decline in the left ventricle.
Preservation of cardiac function in exercised animals was
associated with the prevention of DOX-induced increases
in MDA, suggesting that attenuation of oxidative stress is a
possible explanation. However, the attenuation of oxidative
stress leaves a great deal of speculation as to the exact
mechanism, because the prevention of oxidative stress
could have a number of effects on calcium handling, pro-
tein expression and function, DNA damage and repair,
apoptosis, mitochondrial function, and cardiomyocyte
bioenergetics. Further studies are warranted to investigate
these or other potential mechanisms that lead to the pro-
tective effects of acute exercise before treatment with
DOX. Although we have previously shown that long-term
exercise training can attenuate the acute cardiac dysfunc-
tion associated with DOX, relatively few patients partici-
pate in long-term exercise training before undergoing DOX
treatment. Here we show that a single bout of exercise can
attenuate DOX-mediated cardiac dysfunction, suggesting
that this may be a more clinically relevant means to allevi-
ate DOX-induced cardiotoxicity in those individuals who
have not been physically active before DOX treatment.
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